Proof-of-concept introduces a 3D organoid platform for assessing CAR T cell cytotoxic activity in squamous cell carcinoma, indicating potential clinical application for GPC3-targeted therapy.
This proof-of-concept study introduces a patient-derived 3D organoid platform for functional assessment of CAR T cell cytotoxic activity in HNSCC. Our findings suggest that GPC3-CAR T therapy may be clinically applicable to subsets of patients with HNSCC, while emphasizing the need for functional validation to account for interpatient heterogeneity in clinical translation.
No takes yet. Share an insight, caveat, or question.
Yoon et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: